EMA – Seizing opportunities in a changing medicines landscape

EMA and the Heads of Medicines Agencies (HMA) have published their draft joint EU network strategy to 2028 for an eight-week public consultation.

This is a review and update to the original five-year strategy, which was developed to cover the period 2021 to 2025 (EMANS 2025). Since then, several changes to the regulatory and technological landscape have occurred, some more rapidly than anticipated. For example, the European Union has enacted new legislation to handle public health emergencies and established the Directorate-General for Health Emergency Preparedness and Response (DG HERA) to improve the EU’s crises preparedness. Technological advances, particularly in artificial intelligence, have presented opportunities to transform the way medicines are developed and regulated across the network. Furthermore, the EU has made steps to revise its pharmaceutical legislation in the largest reform of the EU medicines regulation in decades. These changes made it necessary to update the EMANS 2025 and to seize the opportunities that they present.

The draft strategy is accompanied by the reflection paper Towards the European medicines agencies network strategy 2028 (EMANS 2028).

Read this news and find more information on the European medicines agencies network strategy on the EMA Website